Targeting 3-phosphoinositide-dependent protein kinase 1 associated with drug-resistant renal cell carcinoma using new oridonin analogs

Jiancheng Zhou, Eun Jin Yun, Wei Chen, Ye Ding, Kaijie Wu, Bin Wang, Chunyong Ding, Elizabeth Hernandez, John Santoyo, Rey Chen Pong, Haiying Chen, Dalin He, Jia Zhou, Jer Tsong Hsieh

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

The current agents used for renal cell carcinoma (RCC) only exhibit the moderate response rate among patients. Development of drug resistance eventually fuels the need of either more potent drugs or new drugs to target the resistant pathways. Oridonin is a diterpenoid isolated from the Chinese medicinal herb Rabdosia rubescens and has been shown to have antitumor activities in many cancers. We previously developed new synthetic methodologies to modify structurally diversified diterpenoids and designed a series of nitrogen-enriched oridonin analogs. In this study, we screened a variety of oridonin analogs based on their cytotoxicity using MTT assay and identify the most potent candidate, namely, CYD-6-17. CYD-6-17 exhibited a high potency to inhibit the in vitro growth of several drug-resistant RCC cells as well as endothelial cells stimulated by tumor cells at nanomolar range. Delivery of CYD-6-17 significantly inhibited RCC tumor growth using xenograft model. Mechanistically, it targeted the 3-phosphoinositide-dependent protein kinase 1 gene that appeared to be a potent regulator of AKT and was associated with patient survival after targeted therapies. This offers a new rational therapeutic regimen of CYD-6-17 to drug-resistant RCC based on its novel mechanism of action.

Original languageEnglish (US)
Pages (from-to)e2701
JournalCell death & disease
Volume8
Issue number3
DOIs
StatePublished - Mar 23 2017

Fingerprint

3-Phosphoinositide-Dependent Protein Kinases
Renal Cell Carcinoma
Diterpenes
Pharmaceutical Preparations
Isodon
Neoplasms
Medicinal Plants
Growth
Drug Resistance
Heterografts
Nitrogen
Endothelial Cells
Survival
oridonin
Therapeutics
Genes

ASJC Scopus subject areas

  • Immunology
  • Cellular and Molecular Neuroscience
  • Cell Biology
  • Cancer Research

Cite this

Targeting 3-phosphoinositide-dependent protein kinase 1 associated with drug-resistant renal cell carcinoma using new oridonin analogs. / Zhou, Jiancheng; Yun, Eun Jin; Chen, Wei; Ding, Ye; Wu, Kaijie; Wang, Bin; Ding, Chunyong; Hernandez, Elizabeth; Santoyo, John; Pong, Rey Chen; Chen, Haiying; He, Dalin; Zhou, Jia; Hsieh, Jer Tsong.

In: Cell death & disease, Vol. 8, No. 3, 23.03.2017, p. e2701.

Research output: Contribution to journalArticle

Zhou, J, Yun, EJ, Chen, W, Ding, Y, Wu, K, Wang, B, Ding, C, Hernandez, E, Santoyo, J, Pong, RC, Chen, H, He, D, Zhou, J & Hsieh, JT 2017, 'Targeting 3-phosphoinositide-dependent protein kinase 1 associated with drug-resistant renal cell carcinoma using new oridonin analogs', Cell death & disease, vol. 8, no. 3, pp. e2701. https://doi.org/10.1038/cddis.2017.121
Zhou, Jiancheng ; Yun, Eun Jin ; Chen, Wei ; Ding, Ye ; Wu, Kaijie ; Wang, Bin ; Ding, Chunyong ; Hernandez, Elizabeth ; Santoyo, John ; Pong, Rey Chen ; Chen, Haiying ; He, Dalin ; Zhou, Jia ; Hsieh, Jer Tsong. / Targeting 3-phosphoinositide-dependent protein kinase 1 associated with drug-resistant renal cell carcinoma using new oridonin analogs. In: Cell death & disease. 2017 ; Vol. 8, No. 3. pp. e2701.
@article{677356f5ab6f4cc98bf64ed57c96a436,
title = "Targeting 3-phosphoinositide-dependent protein kinase 1 associated with drug-resistant renal cell carcinoma using new oridonin analogs",
abstract = "The current agents used for renal cell carcinoma (RCC) only exhibit the moderate response rate among patients. Development of drug resistance eventually fuels the need of either more potent drugs or new drugs to target the resistant pathways. Oridonin is a diterpenoid isolated from the Chinese medicinal herb Rabdosia rubescens and has been shown to have antitumor activities in many cancers. We previously developed new synthetic methodologies to modify structurally diversified diterpenoids and designed a series of nitrogen-enriched oridonin analogs. In this study, we screened a variety of oridonin analogs based on their cytotoxicity using MTT assay and identify the most potent candidate, namely, CYD-6-17. CYD-6-17 exhibited a high potency to inhibit the in vitro growth of several drug-resistant RCC cells as well as endothelial cells stimulated by tumor cells at nanomolar range. Delivery of CYD-6-17 significantly inhibited RCC tumor growth using xenograft model. Mechanistically, it targeted the 3-phosphoinositide-dependent protein kinase 1 gene that appeared to be a potent regulator of AKT and was associated with patient survival after targeted therapies. This offers a new rational therapeutic regimen of CYD-6-17 to drug-resistant RCC based on its novel mechanism of action.",
author = "Jiancheng Zhou and Yun, {Eun Jin} and Wei Chen and Ye Ding and Kaijie Wu and Bin Wang and Chunyong Ding and Elizabeth Hernandez and John Santoyo and Pong, {Rey Chen} and Haiying Chen and Dalin He and Jia Zhou and Hsieh, {Jer Tsong}",
year = "2017",
month = "3",
day = "23",
doi = "10.1038/cddis.2017.121",
language = "English (US)",
volume = "8",
pages = "e2701",
journal = "Cell Death and Disease",
issn = "2041-4889",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - Targeting 3-phosphoinositide-dependent protein kinase 1 associated with drug-resistant renal cell carcinoma using new oridonin analogs

AU - Zhou, Jiancheng

AU - Yun, Eun Jin

AU - Chen, Wei

AU - Ding, Ye

AU - Wu, Kaijie

AU - Wang, Bin

AU - Ding, Chunyong

AU - Hernandez, Elizabeth

AU - Santoyo, John

AU - Pong, Rey Chen

AU - Chen, Haiying

AU - He, Dalin

AU - Zhou, Jia

AU - Hsieh, Jer Tsong

PY - 2017/3/23

Y1 - 2017/3/23

N2 - The current agents used for renal cell carcinoma (RCC) only exhibit the moderate response rate among patients. Development of drug resistance eventually fuels the need of either more potent drugs or new drugs to target the resistant pathways. Oridonin is a diterpenoid isolated from the Chinese medicinal herb Rabdosia rubescens and has been shown to have antitumor activities in many cancers. We previously developed new synthetic methodologies to modify structurally diversified diterpenoids and designed a series of nitrogen-enriched oridonin analogs. In this study, we screened a variety of oridonin analogs based on their cytotoxicity using MTT assay and identify the most potent candidate, namely, CYD-6-17. CYD-6-17 exhibited a high potency to inhibit the in vitro growth of several drug-resistant RCC cells as well as endothelial cells stimulated by tumor cells at nanomolar range. Delivery of CYD-6-17 significantly inhibited RCC tumor growth using xenograft model. Mechanistically, it targeted the 3-phosphoinositide-dependent protein kinase 1 gene that appeared to be a potent regulator of AKT and was associated with patient survival after targeted therapies. This offers a new rational therapeutic regimen of CYD-6-17 to drug-resistant RCC based on its novel mechanism of action.

AB - The current agents used for renal cell carcinoma (RCC) only exhibit the moderate response rate among patients. Development of drug resistance eventually fuels the need of either more potent drugs or new drugs to target the resistant pathways. Oridonin is a diterpenoid isolated from the Chinese medicinal herb Rabdosia rubescens and has been shown to have antitumor activities in many cancers. We previously developed new synthetic methodologies to modify structurally diversified diterpenoids and designed a series of nitrogen-enriched oridonin analogs. In this study, we screened a variety of oridonin analogs based on their cytotoxicity using MTT assay and identify the most potent candidate, namely, CYD-6-17. CYD-6-17 exhibited a high potency to inhibit the in vitro growth of several drug-resistant RCC cells as well as endothelial cells stimulated by tumor cells at nanomolar range. Delivery of CYD-6-17 significantly inhibited RCC tumor growth using xenograft model. Mechanistically, it targeted the 3-phosphoinositide-dependent protein kinase 1 gene that appeared to be a potent regulator of AKT and was associated with patient survival after targeted therapies. This offers a new rational therapeutic regimen of CYD-6-17 to drug-resistant RCC based on its novel mechanism of action.

UR - http://www.scopus.com/inward/record.url?scp=85032883188&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85032883188&partnerID=8YFLogxK

U2 - 10.1038/cddis.2017.121

DO - 10.1038/cddis.2017.121

M3 - Article

C2 - 28333136

AN - SCOPUS:85032883188

VL - 8

SP - e2701

JO - Cell Death and Disease

JF - Cell Death and Disease

SN - 2041-4889

IS - 3

ER -